



Healthware Consulting Ltd.

H-1093 Budapest Közraktár st. 30-32. 7th floor. I + 36-1-324-2050

in

Source: Healthware analysis based on NHIFA data



Market data

GILENYA

TASIGNA

Sanofi

Pfizer

EGIS

TEVA

Sandoz

Richter Gedeon

Novo Nordisk

JANSSEN-CILAG

Boehringer Ingelheim

Average number of medical sales reps Toplists of reimbursement and number of patients, March 2019 TOP 10 ATCs by all reimbursement paid enoxaparin 728 M Ft other nutrients 671 M Ft ruxolitinib 609 M Ft paliperidone 589 M Ft Share of TOP 10 active rivaroxaban 482 M Ft rosuvastatin 449 M Ft dimethyl fumarate 420 M Ft palbociclib 414 M Ft insulin glargine 378 M Ft subs apixaban 378 M Ft Source: Pharmacy turnover data, Healthware analysis TOP 10 brands by all reimbursement paid CLEXANE 728 M Ft JAKAVI 609 M Ft XARELTO 333 482 M Ft TECFIDERA 420 M F 309 IBRANCE 414 M F1 Share of TOP 10 ELIQUIS 378 M Ft XEPLION 355 M Ft 261 XULTOPHY 337 M Ft

Source: NHIFA data, Healthware analysis

TOP 10 active substances by number of patients (thousand patients)



Health spending structure - out-of-pocket or voluntary health insurance? - case study

314 M Ft

TOP 10 distributors by all reimbursement paid

1 725 M Ft

1 693 M Ft

2 060 M Ft

1 974 M Ft

307 M Ft

1 449 M Ft

1 309 M Ft

1 188 M Ft

1 081 M F

963 M Ft

In June 2019, the colleagues of Healthware Ltd. prepare several topics for the XIII. National Health although, its health spending per capita is higher than in the countries mentioned above, as well as in

Economics Training and Conference. Our current case study shows the starting points of our Poland, Croatia, and Estonia. In this perspective, only the Czech Republic, Slovakia, and Slovenia are ahead of us in the region.

brands

Share of TOP 10 distributor:

3 187 M Ft

Source: Pharmacy turnover data, Healthware analysis

Source: Pharmacy turnover data, Healthware analy

amenabl

In February 2019, the Central Bank of Hungary published a 330-point package of proposals which Figure 2. shows the out-ofprove the competitiveness of the Hungarian economy. The document focuses on the s of the health care system and formulates a number of suggestions on prevention authors state in the document, that the core problem of the system is that household expenditures

not spent in institutionalized accounts or complementary private

Hungarian health expenditures are statistics, Hungarian data show a that in terms of amenable death

Figure 1: Health spending by financial schemes per inhabitant in Eastern Europe:Purchasing power standard (PPS) per inhabitant - by amenable death - 2016



pocket spending, and GDP pe death rates countries. Based on these Eastern European countries per m to have a correlation compensate the deficiencie disproportionately high extent of direct health spending, - in the light of the mortality rates - without

Figure 2. Relation between amenable death rates and out-of-pocket hitant (2016) The size and the colour of the bubbles shows the GDP (in PPS per inhabitant - index EU27=100) of the country (2016) - 65 🔵 66 - 90 🛑 91 - 115 - Source: Eurostat

of a direct, out-of-pocket spending, as a more effective way of spending the existing sources. The prerequisite for this is the clear separation of the public and private healthcare. The latter is to get benefits or services at all in public healthcare

in

H-1093 Budapest Közraktár st. 30-32. 7th floor I + 36-1-324-2050

Subscribe



Actualities of Hungarian pharmaceutical financing market

Health spending structure - out-of-pocket or voluntary health insurance? — case study

In the model outlined by analysts of the National Bank, tax advantages and normative incentives would result in the majority of the population being covered by complementary insurance. This complementary insurance can be used for buying private health services, while health fund an example, where voluntary health insurance payments are the highest in the proportion of the total statistics in amenable death

However, it is also worth noting that in Slovenia, per capita (in PPS) public health expenditures exceeds those occurred in Hungary. In proportion to GDP, Slovenian public spending exceeded the Hungarian one by 1% in 2017, which means that an increase of around 400 billion forints would be needed to reach at least proportionally the level of our southwestern neighbor in public health spending.

In our presentation at IME conference, based on the trends of the past years of Eastern European and especially Hungarian private financing, we are looking for an answer whether the shifting of household expenditures towards institutionalized forms can improve the perceived and objective health indicators of Hungary.

Source: MNB — 330-point Competitiveness Programme https://www.mnb.hiu/Kiadvanyok/jelentesek/versenykepessegi-program-330-pontba WHO — Estimating health expenditure shares from household surveys https://www.who.int/bulletin/volumes/91/7/12-115535/en/ WHO — Validity and Comparability of 01-ofpocket Health Expenditure from Household Surv https://www.who.int/health_financing/documents/dp_e_11_01-oop_errors.pdf WHO — Valnary health insurance: patentials and limits in moving towards UHC https://www.who.int/health_financing/documents/voluntary-health-insurance/en/ Source of Eurostat data: https://ec.europa.eu/eurostat/data/database

